Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWeight loss injections such as Mounjaro (tirzepatide) and Wegovy (semaglutide) reduce overall body weight, and clinical trials show that abdominal fat decreases alongside it — though the body decides where it loses fat from, not you or your prescriber. In SURMOUNT-1, participants using tirzepatide at the highest dose lost around 20–21% of their body weight over 72 weeks, and a meaningful portion of that was visceral fat carried around the middle. These are prescription-only medicines; a clinician assesses whether they are suitable for you before any treatment begins. If you are wondering whether weight loss injections really work more broadly, the evidence base is substantial — but belly fat specifically raises its own questions, and they are worth answering carefully.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Spot reduction is a myth that exercise marketing pushed for decades, and the same logic applies to medicines. Weight loss injections do not instruct your body to burn fat from a specific place. What they do is suppress appetite through gut-hormone pathways, slow gastric emptying and reduce overall calorie intake over time, and as total body fat falls, abdominal fat tends to come down with it.
The reason belly fat features so prominently in conversations about these medicines is that visceral fat (the fat wrapped around organs inside the abdomen) responds particularly well to sustained calorie deficits. It is metabolically active tissue, and it tends to shift earlier than subcutaneous fat in a period of significant weight loss. Trial data support this: in SURMOUNT-1, published in the New England Journal of Medicine, participants on tirzepatide 15mg saw an average body-weight reduction of around 20–21% over 72 weeks. Waist circumference fell substantially across the trial population. That is not spot reduction, it is the body redistributing as overall mass drops.
Semaglutide (Wegovy) showed similar patterns in the STEP 1 trial: around 15% average weight loss over 68 weeks, with measurable reductions in abdominal circumference. The NHS medicines page for tirzepatide explains how the medicine works in plain language if you want more detail on the mechanism.
So yes, injections work for belly fat, in the sense that a significant overall weight loss will reduce it. No, they cannot be aimed at it exclusively.
It is, and the distinction matters for health. Subcutaneous fat sits just below the skin, it is the kind you feel when you press your abdomen. Visceral fat is deeper, packed around the liver, pancreas and intestines, and it is more closely linked to insulin resistance, type 2 diabetes risk, raised blood pressure and cardiovascular disease.
This is one reason clinicians and researchers pay close attention to waist circumference as a health marker, not just weight on scales. Losing visceral fat has measurable metabolic benefits beyond appearance. People who have completed longer courses of GLP-1 treatment often describe their waistband fitting differently before the scales shift dramatically, which fits the pattern of visceral fat reducing early.
If you are curious about how weight loss injections work at a biological level, the mechanism involves the gut hormones GLP-1 and, in tirzepatide's case, GIP as well, both influence appetite signalling, energy regulation and how the body processes food. Understanding that helps explain why sustained use produces the kind of fat loss that shows around the middle.
One honest note: loose skin or subcutaneous fat that remains after significant weight loss may not resolve with the injection alone. That is a separate conversation, and not one a weight-loss medicine is designed for.
Both Mounjaro and Wegovy are licensed in the UK for adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, raised cholesterol, obstructive sleep apnoea or type 2 diabetes. Lower thresholds apply for some ethnic backgrounds under UK guidance. BMI is the starting point, not the whole picture. A prescriber looks at your medical history, current medicines, and any conditions that could affect safety before deciding whether treatment is appropriate.
These are not available over the counter. If you have seen something described as an over-the-counter weight loss injection, it is worth being sceptical: the licensed medicines require a prescription, and the MHRA has warned publicly about counterfeit pens sold without clinical oversight. Fakes have caused serious harm. The only legitimate route is through a regulated prescriber.
On the question of cost, treatment pricing at nume covers the consultation, prescription, and free next-working-day delivery in one transparent figure, no subscription, no add-on fees. That context matters when you are comparing options, because a headline price that excludes the clinical assessment is not a complete price.
If you want to understand the full range of options, the weight loss treatments overview covers what is licensed, how the options differ, and what a clinical assessment involves.
The most common ones are gastrointestinal: nausea, loose stools, constipation, indigestion and burping are regularly reported, particularly in the first few weeks of treatment or after a dose increase. Most people find these settle as their body adjusts. They are less about the medicine being harmful and more about the gut adapting to a slower rate of emptying.
One thing our prescribers raise with patients before they start: the medicine arrives in plain, unbranded packaging via DPD with full tracking, there is nothing on the box that identifies what is inside. What is inside is a pre-filled pen; it needs to go straight into the fridge. If you want to know more about the belly injection for weight loss and how the abdomen is commonly used as an injection site, that covers the practicalities in useful detail. Injections are given once weekly, rotating between the abdomen, thigh or upper arm.
On the more serious end, the MHRA issued guidance in January 2026 flagging acute pancreatitis as an infrequent but serious risk: severe stomach pain that radiates to the back, with or without vomiting, needs urgent medical attention. Patients can report unexpected effects through the Yellow Card scheme. Women using oral contraceptives who start tirzepatide should add a non-oral method for the first four weeks and after each dose increase, as absorption of the pill may be affected, discuss this with your GP or prescriber before starting. If you are considering fat injections for weight loss and want to understand how they compare to the licensed options available in the UK, that page sets out what is known about the different approaches.
For a fuller picture of how these medicines are used, our guide to weight loss injections in the UK covers the practicalities in more depth. And if you are ready to find out whether you are eligible, you can check your eligibility with our prescribers, consultations are free, and reviewed by a real clinician the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.